Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05932901 · ClinicalTrials.gov registry record
OPTIMISE-CKD Drug Utilization
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,682,052
- Enrollment target
NCT05932901: Completed study, sponsored by AstraZeneca.
NCT05932901 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 2,682,052 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05932901 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,682,052 participants
- Enrollment target
Study Summary
This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin in CKD (pending feasibility assessment).
Primary Outcome
Patient demographic characteristics including age, sex, race and insurance type (if data are available)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,682,052 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2023-09-28 |
What the finished NCT05932901 record still lists
NCT05932901 is an observational study that tracks outcomes without assigning an intervention. Its 2,682,052 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05932901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05932901 about?
NCT05932901 is a clinical study titled "OPTIMISE-CKD Drug Utilization". This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin i...
What is the current status of trial NCT05932901?
This trial is currently completed. The enrollment target is 2,682,052 participants. The study started on 2022-05-04. Estimated completion is 2023-09-28.
Who is sponsoring clinical trial NCT05932901?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI